Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a Minimum of $3,800,000 of Debt Conversion
(WorldNews Health)

NEW YORK, April 7, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the entering of a significant financial transaction with its lead investor, Yorkville Advisors Global (`YA`). Under the agreement, on closing, YA will have converted a minimum of $3,800,000 into common stock and preferred stock and may convert an additional $500,000 which would be the total debt held by them. As part of the agreement, YA will fund an additional $4,000,000 in new capital over the next 2 weeks. This restructuring of the debt and new capital transforms the Company`s balance sheet creating significant positive shareholder equity,...